FDA Publishes Four Final Device Orders on October 6, 2026: Three New Device Types Classified as Class II, One Class II Clinical Toxicology Test System Exempt from 510(k)

FDA Publishes Four Final Device Orders in a Single Batch on October 6, 2026: Three New Device Types Classified as Class II, One Class II Clinical Toxicology Test System Exempt from 510(k)

On October 6, 2026, the U.S. Food and Drug Administration (FDA) published four final medical device orders in Volume 91, Issue 192 of the Federal Register, all effective the same day. Three of them are classification orders that formally place three new device types, previously established through the De Novo classification process, into Class II with special controls. One is a 510(k) exemption order that removes certain Class II clinical toxicology test systems from premarket notification. The orders were led by FDA's Center for Devices and Radiological Health (CDRH) and issued under the Federal Food, Drug, and Cosmetic Act.

Order 1: Hyperoxia Monitoring Device Adjunct to Pulse Oximetry

The first order addresses the Hyperoxia Monitoring Device Adjunct to Pulse Oximetry, classified under 21 CFR Part 870 (Cardiovascular Devices). The order is effective October 6, 2026, with a classification applicability date of October 12, 2023. The document states that this device type originated from a De Novo classification request submitted by Masimo Corporation on December 21, 2020, corresponding to the ORi device. FDA determined that Class II with special controls provides reasonable assurance of safety and effectiveness.

Order 2: Focused Ultrasound System for Non-Thermal, Mechanical Tissue Ablation

The second order addresses the Focused Ultrasound System for Non-Thermal, Mechanical Tissue Ablation, classified under General and Plastic Surgery Devices; it is likewise placed in Class II with special controls. The order is effective October 6, 2026, with a classification applicability date of October 6, 2023.

Order 3: High Throughput DNA Sequencing for Hereditary Cancer Predisposition Assessment Test System

The third order addresses the High Throughput DNA Sequencing for Hereditary Cancer Predisposition Assessment Test System, classified under Immunology and Microbiology Devices, that is, within the in vitro diagnostic (IVD) category, and placed in Class II with special controls. The order is effective October 6, 2026, with a classification applicability date of September 29, 2023.

Order 4: Exemption from Premarket Notification for Certain Class II Clinical Toxicology Test Systems

The fourth order is an exemption order. FDA exempts certain Class II clinical toxicology test systems from the 510(k) premarket notification requirement, subject to limitations. The order is effective immediately and concurrently amends the classification language of the relevant sections in 21 CFR Part 862, including 862.3100, 862.3150, 862.3170, 862.3250, 862.3270, 862.3580, 862.3610, 862.3620, 862.3630, 862.3640, 862.3650, 862.3700, 862.3870 and 862.3910. FDA's stated rationale is to reduce the regulatory burden on industry and to lower compliance costs.

A Point That Is Easy to Misread

The applicability dates of the De Novo classifications stop at 2023. This batch of orders is the final step that writes those classifications into the federal regulations, and the effective date of the orders is October 6, 2026. Each set of dates serves a distinct purpose and the two must not be conflated when cited.

A Point with a More Direct Impact

Once a device type is classified as Class II, it can itself serve as a predicate device for later, similar products, so other manufacturers no longer need to pursue the De Novo or PMA pathway and may submit a 510(k) instead. This is the burden-reduction logic FDA identifies in the orders, and it is why a final classification is more worth monitoring than an individual clearance.

Use the Exemption Fully, but Define Its Boundaries

The exemption should be used to the full, but its boundaries must be clearly drawn. It covers only the Class II clinical toxicology test systems listed in the order and is subject to limitations. It does not mean that those test systems fall outside other device requirements, and it does not cover products that are not listed. Companies that market under the exemption must still retain evidence of compliance with the limitations.

AIMEILI Regulatory Interpretation

The four orders should be read as two distinct regulatory mechanisms operating on the same day. The three classification orders convert De Novo classifications, granted in 2023, into codified Class II classifications with special controls in the CFR. The practical consequence is that each device type acquires a durable regulatory identity: a classification regulation, a product code, and the status of a potential predicate device. From that point, a subsequent manufacturer of a substantially equivalent device can generally rely on the 510(k) pathway rather than De Novo or PMA, provided it meets the applicable special controls and demonstrates substantial equivalence. The classification applicability date (the De Novo date) governs the regulatory status of devices already on the market or submitted in the interim period, while the October 6, 2026 effective date governs when the codified regulation and the predicate-eligibility logic formally take hold.

The fourth order is an exemption rather than a classification. Under section 510(m) of the Federal Food, Drug, and Cosmetic Act, FDA may exempt a Class II device type from premarket notification if it determines that premarket notification is not necessary to provide reasonable assurance of safety and effectiveness. The exemption is limited: it applies only to the device types and conditions specified in the order, and it does not relieve manufacturers of establishment registration and device listing, the Quality Management System Regulation (21 CFR Part 820, as revised by QMSR), labeling requirements, medical device reporting (MDR), corrections and removals reporting, or any other applicable requirement. Where a manufacturer cannot meet the stated limitations, or where a device falls outside the enumerated types, the 510(k) requirement continues to apply. Documentation demonstrating continued compliance with the exemption's limitations should be maintained and available for inspection.

Business Impact for Manufacturers, Distributors, CROs and Regulatory Affairs Teams

• New predicate options: Pulse oximetry adjuncts for hyperoxia monitoring, focused ultrasound systems for non-thermal mechanical tissue ablation, and high throughput DNA sequencing test systems for hereditary cancer predisposition assessment can now be cited as predicates. This can shorten development and submission timelines for substantially equivalent devices and may reduce reliance on the De Novo and PMA routes.
• Special controls compliance becomes the critical path: A Class II designation with special controls carries mandatory performance and labeling expectations. Regulatory teams should confirm the specific special controls cited in each order, since they define the evidence package for a 510(k) and for post-market compliance.
• Date discipline in regulatory documents: Distinguish the classification applicability dates (October 12, 2023; October 6, 2023; September 29, 2023) from the October 6, 2026 effective date when drafting regulatory strategy memos, 510(k) submissions, technical files or client advisories.
• Scope control for the exemption: Clinical toxicology assay developers should verify whether their specific assay falls within an amended 21 CFR 862 section and whether the limitations are met. If not, the 510(k) pathway remains mandatory, and internal decision records should document the exemption analysis.
• Competitive and pipeline planning: IVD developers in hereditary cancer predisposition testing should reassess whether a predicate-based 510(k) route is now viable, which may affect evidence-generation plans, clinical validation strategy and time-to-market estimates.
• Regulatory monitoring: The orders take effect immediately, and FDA may issue further updates, guidance or additional exemptions. Companies should track CDRH communications and Federal Register notices for any subsequent amendments to the affected CFR sections.

Sources and Scope of Verification

Sources: The four final orders published by the U.S. Food and Drug Administration (FDA) in the Federal Register. Verification pages:

• U.S. Food and Drug Administration (FDA) — Federal Register: Classification of the Hyperoxia Monitoring Device Adjunct to Pulse Oximetry: https://www.federalregister.gov/documents/2026/10/06/2026-20441/medical-devices-cardiovascular-devices-classification-of-the-hyperoxia-monitoring-device-adjunct-to
• U.S. Food and Drug Administration (FDA) — Federal Register: Classification of the Focused Ultrasound System for Non-Thermal, Mechanical Tissue Ablation: https://www.federalregister.gov/documents/2026/10/06/2026-20440/medical-devices-general-and-plastic-surgery-devices-classification-of-the-focused-ultrasound-system
• U.S. Food and Drug Administration (FDA) — Federal Register: Classification of the High Throughput DNA Sequencing for Hereditary Cancer Predisposition Assessment: https://www.federalregister.gov/documents/2026/10/06/2026-20443/medical-devices-immunology-and-microbiology-devices-classification-of-the-high-throughput-dna
• U.S. Food and Drug Administration (FDA) — Federal Register: Exemptions from Premarket Notification: Class II Devices; Certain Clinical Toxicology Test Systems: https://www.federalregister.gov/documents/2026/10/06/2026-20448/medical-devices-exemptions-from-premarket-notification-class-ii-devices-certain-clinical-toxicology
• U.S. Food and Drug Administration (FDA) — CDRH New: News and Updates: https://www.fda.gov/medical-devices/medical-devices-news-and-events/cdrh-new-news-and-updates

The publication and effective dates of all four orders are October 6, 2026. The CDRH New — News and Updates page was also checked to cross-confirm the public announcement of the four orders.

Scope of verification and access date: The four Federal Register order pages and the CDRH New page were verified on October 7, 2026. The classification applicability dates, effective dates, device type names and CFR section numbers stated in the order texts are based on the content published on the official pages listed above.

Applicability note: This article is an interpretation of publicly available regulatory information and does not constitute a conclusion or commitment regarding any specific product, company or registration application. The classification pathways and exemption scope are governed by the official texts and subsequent official updates, and the information may change as the agency revises its materials.